281 related articles for article (PubMed ID: 27148629)
21. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo.
Malik N; Wiwattanapatapee R; Klopsch R; Lorenz K; Frey H; Weener JW; Meijer EW; Paulus W; Duncan R
J Control Release; 2000 Mar; 65(1-2):133-48. PubMed ID: 10699277
[TBL] [Abstract][Full Text] [Related]
22. TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations.
Bielski E; Zhong Q; Mirza H; Brown M; Molla A; Carvajal T; da Rocha SRP
Int J Pharm; 2017 Jul; 527(1-2):171-183. PubMed ID: 28549971
[TBL] [Abstract][Full Text] [Related]
23. PEGylated nanocarriers for systemic delivery.
Jain NK; Nahar M
Methods Mol Biol; 2010; 624():221-34. PubMed ID: 20217599
[TBL] [Abstract][Full Text] [Related]
24. PEGylated PAMAM dendrimers: Enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery.
Luong D; Kesharwani P; Deshmukh R; Mohd Amin MCI; Gupta U; Greish K; Iyer AK
Acta Biomater; 2016 Oct; 43():14-29. PubMed ID: 27422195
[TBL] [Abstract][Full Text] [Related]
25. α-Tocopherol Succinate-Anchored PEGylated Poly(amidoamine) Dendrimer for the Delivery of Paclitaxel: Assessment of in Vitro and in Vivo Therapeutic Efficacy.
Bhatt H; Kiran Rompicharla SV; Ghosh B; Biswas S
Mol Pharm; 2019 Apr; 16(4):1541-1554. PubMed ID: 30817166
[TBL] [Abstract][Full Text] [Related]
26. Size and Surface Charge of Engineered Poly(amidoamine) Dendrimers Modulate Tumor Accumulation and Penetration: A Model Study Using Multicellular Tumor Spheroids.
Bugno J; Hsu HJ; Pearson RM; Noh H; Hong S
Mol Pharm; 2016 Jul; 13(7):2155-63. PubMed ID: 26828309
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin.
Kirkpatrick GJ; Plumb JA; Sutcliffe OB; Flint DJ; Wheate NJ
J Inorg Biochem; 2011 Sep; 105(9):1115-22. PubMed ID: 21704583
[TBL] [Abstract][Full Text] [Related]
28. PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization.
Nasr M; Najlah M; D'Emanuele A; Elhissi A
Int J Pharm; 2014 Jan; 461(1-2):242-50. PubMed ID: 24275446
[TBL] [Abstract][Full Text] [Related]
29. Prolonged blood circulation and enhanced tumor accumulation of folate-targeted dendrimer-polymer hybrid nanoparticles.
Sunoqrot S; Bugno J; Lantvit D; Burdette JE; Hong S
J Control Release; 2014 Oct; 191():115-22. PubMed ID: 24837188
[TBL] [Abstract][Full Text] [Related]
30. Biodistribution of fluorescently labeled PAMAM dendrimers in neonatal rabbits: effect of neuroinflammation.
Lesniak WG; Mishra MK; Jyoti A; Balakrishnan B; Zhang F; Nance E; Romero R; Kannan S; Kannan RM
Mol Pharm; 2013 Dec; 10(12):4560-71. PubMed ID: 24116950
[TBL] [Abstract][Full Text] [Related]
31. Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration.
Mcleod VM; Chan LJ; Ryan GM; Porter CJ; Kaminskas LM
J Pharm Sci; 2015 Apr; 104(4):1421-30. PubMed ID: 25631360
[TBL] [Abstract][Full Text] [Related]
32. Modulated cellular delivery of anti-VEGF siRNA (bevasiranib) by incorporating supramolecular assemblies of hydrophobically modified polyamidoamine dendrimer in stealth liposomes.
Golkar N; Samani SM; Tamaddon AM
Int J Pharm; 2016 Aug; 510(1):30-41. PubMed ID: 27291973
[TBL] [Abstract][Full Text] [Related]
33. Stealth dendrimers for drug delivery: correlation between PEGylation, cytocompatibility, and drug payload.
Yang H; Lopina ST; DiPersio LP; Schmidt SP
J Mater Sci Mater Med; 2008 May; 19(5):1991-7. PubMed ID: 17952565
[TBL] [Abstract][Full Text] [Related]
34. Redox and pH dual responsive poly(amidoamine) dendrimer-poly(ethylene glycol) conjugates for intracellular delivery of doxorubicin.
Hu W; Qiu L; Cheng L; Hu Q; Liu Y; Hu Z; Chen D; Cheng L
Acta Biomater; 2016 May; 36():241-53. PubMed ID: 26995505
[TBL] [Abstract][Full Text] [Related]
35. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin.
Ryan GM; Kaminskas LM; Bulitta JB; McIntosh MP; Owen DJ; Porter CJH
J Control Release; 2013 Nov; 172(1):128-136. PubMed ID: 23954628
[TBL] [Abstract][Full Text] [Related]
36. BR2 and CyLoP1 enhance in-vivo SN38 delivery using pegylated PAMAM dendrimers.
Mahmoudi A; Jaafari MR; Ramezanian N; Gholami L; Malaekeh-Nikouei B
Int J Pharm; 2019 Jun; 564():77-89. PubMed ID: 30991135
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin.
Bai S; Ahsan F
Pharm Res; 2009 Mar; 26(3):539-48. PubMed ID: 19034631
[TBL] [Abstract][Full Text] [Related]
38. Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers.
Kojima C; Regino C; Umeda Y; Kobayashi H; Kono K
Int J Pharm; 2010 Jan; 383(1-2):293-6. PubMed ID: 19761822
[TBL] [Abstract][Full Text] [Related]
39. PEGylated thermo-sensitive poly(amidoamine) dendritic drug delivery systems.
Zhao Y; Fan X; Liu D; Wang Z
Int J Pharm; 2011 May; 409(1-2):229-36. PubMed ID: 21316434
[TBL] [Abstract][Full Text] [Related]
40. Development of PEGylated carboxylic acid-modified polyamidoamine dendrimers as bone-targeting carriers for the treatment of bone diseases.
Yamashita S; Katsumi H; Hibino N; Isobe Y; Yagi Y; Kusamori K; Sakane T; Yamamoto A
J Control Release; 2017 Sep; 262():10-17. PubMed ID: 28710004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
